Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Workshop on growth factors.

D Crowther1, M B Sporn, A B Roberts

  • 1Christie Hospital, Manchester, UK.

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|February 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immunologic Aspects of the Hematologic Neoplasms.

Postgraduate medicine·2016
Same author

Cardioprotective actions of transforming growth factor-β.

Trends in cardiovascular medicine·2011
Same author

Functional redundancy of TGF-beta family type I receptors and receptor-Smads in mediating anti-Mullerian hormone-induced Mullerian duct regression in the mouse.

Biology of reproduction·2008
Same author

Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.

Leukemia·2007
Same author

Smad3 deficiency inhibits v-ras-induced transformation by suppression of JNK MAPK signaling and increased farnesyl transferase inhibition.

Oncogene·2007
Same author

Targeted mutagenesis of Smad1 reveals an essential role in chorioallantoic fusion.

Developmental biology·2002
Same journal

The ethical obligation to use positive trial results.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

Lorlatinib: The Crown Jewel of ALK Inhibitors.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

TROP2-Directed Antibody Drug Conjugates: New First-Line Treatment for All Patients with Advanced Triple-Negative Breast Cancer?

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

When artificial intelligence learns to abstain: towards clinically responsible diagnostic support in liver pathology.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

PRMT5 inhibitors in MTAP loss NSCLC with actionable genomic alterations: a new kid on the block?

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

Refining decision making in hormone receptor-positive early-stage breast cancer: moving from static to dynamic.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
See all related articles

Growth factors like TGF-beta and IL-6 are crucial in cancer development and treatment. Research explores antibodies and hematopoietic growth factors (G-CSF, GM-CSF) to combat human cancers, including myeloma and lymphoma.

Area of Science:

  • Oncology and Experimental Biology
  • Immunology and Cancer Therapeutics

Background:

  • Discusses the role of growth factors in human cancer development, focusing on the loss of inhibitory control mechanisms.
  • Highlights transforming growth factor beta (TGF-beta) interactions and interleukin-6 (IL-6) in plasma cell diseases.

Framework:

  • Explores the biological functions of IL-6 and its potential therapeutic targeting in myeloma.
  • Introduces the concept of using antibodies against growth factors as a novel cancer therapy.

Implementation:

  • Presents the first clinical study using an anti-IL-6 antibody for myeloma treatment.
  • Details the clinical application of hematopoietic growth factors, including G-CSF and GM-CSF, in chemotherapy.

Implications:

Related Experiment Videos

  • Demonstrates the efficacy of G-CSF and GM-CSF in improving neutrophil recovery and safety during high-dose chemotherapy.
  • Suggests potential applications of G-CSF and GM-CSF in conjunction with chemotherapy for malignant lymphoma patients.